Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
Pasithea Therapeutics (Nasdaq: KTTA) will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference in a virtual session on Thursday, February 26, 2026 at 4:00 PM ET. CEO Tiago Reis Marques will deliver a 30-minute presentation in Track 2 and management will be available for one-on-one investor meetings.
The presentation will be webcast live and archived for a limited time on the company’s Investors > Events page; a replay will be available after the live event. Registration for the conference is required to join meetings.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
KTTA was up 1.44% while high-affinity biotech peers like SXTP, ADTX, TNFA and others showed declines between about 1–11%, indicating stock-specific trading rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 13 | Program outlook update | Positive | -3.3% | Updated PAS-004 clinical timelines and highlighted funding through at least H1 2028. |
| Dec 02 | Offering closing | Positive | +2.6% | Closed <b>$60M</b> offering at <b>$0.75</b> to support R&D and extend cash runway. |
| Nov 28 | Offering pricing | Positive | +38.7% | Priced <b>$60M</b> equity deal, signaling investor support and improved liquidity. |
| Nov 25 | ALS grant news | Positive | +14.8% | ALS Association grant of about <b>$1M</b> to fund Phase 1 PAS-004 ALS study. |
| Nov 24 | Phase 1 data update | Positive | +45.3% | Reported positive safety, PK and PD data from Cohort 7 in PAS-004 cancer trial. |
Recent history shows strong upside reactions to positive clinical and financing updates, with one notable divergence where a constructive PAS-004 outlook coincided with a modest price pullback.
Over the last several months, Pasithea has focused on advancing PAS-004 across NF1-PN, advanced cancers and ALS while repeatedly strengthening its balance sheet. Positive Phase 1 safety, PK and PD data and a Hoffman ALS grant of about $1 million drew strong price gains, as did November and December 2025 equity offerings that extended the cash runway through at least the first half of 2028. The current conference presentation fits into this ongoing effort to showcase PAS-004 and engage investors.
Market Pulse Summary
This announcement highlights Pasithea’s participation in a major healthcare conference, offering additional visibility for PAS-004, its macrocyclic MEK inhibitor for NF1-PN. Recent history shows meaningful milestones, including positive Phase 1 data and non-dilutive ALS grant funding, alongside substantial equity raises to extend the cash runway through at least the first half of 2028. Investors may watch for updates on clinical timelines, data readouts, and how management communicates development priorities during the presentation.
Key Terms
mek inhibitor medical
AI-generated analysis. Not financial advice.
– Virtual presentation scheduled for Thursday, February 26, 2026, at 4:00 PM ET –
– Webcast may be accessed here –
MIAMI, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of NF1-associated plexiform neurofibromas (NF1-PN), today announced that Chief Executive Officer Tiago Reis Marques will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in a virtual format February 25–26, 2026.
The Company’s presentation is scheduled for Thursday, Feb 26 at 4:00-4:30 PM ET in Track 2, and the webcast may be viewed here.
In addition to the presentation, management will be available for one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
A live webcast of the presentation will be accessible on the Events page in the Investors section of the Company’s website. A replay will be available following the live event and will be archived for a limited time.
About Pasithea Therapeutics Corp.
Pasithea is a clinical-stage biotechnology company primarily focused on the research and development of its lead drug candidate, PAS-004, a next-generation macrocyclic MEK inhibitor intended for the treatment of RASopathies, MAPK pathway-driven tumors, and other diseases. The Company is currently testing PAS-004 in a Phase 1 clinical trial in advanced cancer patients (NCT06299839), and a Phase 1/1b clinical trial in adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (NCT06961565).
Forward Looking Statements
This press release contains statements that constitute “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the Company’s ongoing Phase 1 clinical trial of PAS-004 in advanced cancer patients, the Company’s Phase 1/1b clinical trial of PAS-004 in adult NF1 patients, and the safety, tolerability, pharmacokinetic (PK), pharmacodynamics (PD) and preliminary efficacy of PAS-004, as well as all other statements, other than statements of historical fact, regarding the Company’s current views and assumptions with respect to future events regarding its business, as well as other statements with respect to the Company’s plans, assumptions, expectations, beliefs and objectives, the success of the Company’s current and future business strategies, product development, pre-clinical studies, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth and financing opportunities and other statements that are predictive in nature. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including risks that future clinical trial results may not match results observed to date, may be negative or ambiguous, or may not reach the level of statistical significance required for regulatory approval, as well as other factors set forth in the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and other filings made with the U.S. Securities and Exchange Commission (SEC). Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law.
Pasithea Therapeutics Contact
Patrick Gaynes
Investor Relations
pgaynes@pasithea.com
FAQ
When is Pasithea Therapeutics (KTTA) presenting at the Oppenheimer conference in 2026?
How can investors watch the Pasithea (KTTA) webcast for the February 26, 2026 presentation?
Who from Pasithea (KTTA) will present at the Oppenheimer Healthcare Life Sciences Conference?
Will Pasithea (KTTA) offer investor meetings at the Oppenheimer conference on February 25–26, 2026?
How long will Pasithea’s (KTTA) presentation last at the February 26, 2026 event?
Where will the replay of Pasithea’s (KTTA) Oppenheimer presentation be available and for how long?
